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Background: Distinct asthma phenotypes have previously been suggested, including benign 
asthma, atopic asthma and obese non-eosinophilic asthma. This study aims to establish if these 
phenotypes can be identified using data recorded in primary care clinical records and reports 
on patient characteristics and exacerbation frequency.
Methods: A population-based cohort study identified 193,999 asthma patients in UK primary 
care from 2007 to 2017. We used linked primary and secondary care data from the Clinical 
Practice Research Datalink, Hospital Episode Statistics and Office for National Statistics. Patients 
were classified into predefined phenotypes or included in an asthma “not otherwise specified” 
(NOS) group. We used negative binomial regression to calculate the exacerbation rates and 
adjusted rate ratios. Rate ratios were further stratified by asthma treatment step.
Results: In our cohort, 3.9% of patients were categorized as benign asthma, 28.6% atopic 
asthma and 4.8% obese non-eosinophilic asthma. About 62.7% of patients were asthma NOS, 
including asthma NOS without treatment (10.4%), only on short-acting beta agonist (6.1%) and 
on maintenance treatment (46.2%). Crude severe exacerbation rates per 1,000 person-years were 
lowest for benign asthma (106.8 [95% CI: 101.2–112.3]) and highest for obese non-eosinophilic 
asthma (469.0 [451.7–486.2]). Incidence rate ratios for all phenotype groups decreased when 
stratified by treatment step but remained raised compared to benign asthma.
Conclusion: Established phenotypes can be identified in a general asthma population, although 
many patients did not fit into the specific phenotypes which we studied. Phenotyping patients 
and knowledge of asthma treatment step could help anticipate clinical course and therefore 
could aid clinical management but is only possible in a minority of primary care patients based 
on current phenotypes and electronic health records (EHRs).
Keywords: asthma, phenotypes, primary health care, electronic health records, epidemiology, 
phenotyping
Introduction
Asthma is a heterogeneous disease with recognizable clusters called asthma phe-
notypes.1–4 These phenotypes are defined as the set of observable characteristics of 
an individual resulting from the interaction of its genotype with the environment.5 
Classifying asthma into phenotypes allows to deconstruct the disease into separate 
identifiable and treatable traits6 and better understand disease progression and response 
to treatment, further enabling practice of precision medicine.2
There have been multiple studies describing asthma phenotypes,7–17 involving popula-
tions with asthma alone or as part of an entity called “obstructive airways disease” together 
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with COPD.18,19 Criteria to distinguish asthma phenotypes 
include  inflammatory profiling based on leukocyte counts 
(eosinophils, neutrophils and paucigranulocytic), symptom 
expression, age-of-asthma onset and airflow measurements.20–26 
Classification by eosinophil counts has been found to be par-
ticularly important due to treatment response.27–29
Haldar et al conducted one of the most impactful studies 
on clinical asthma phenotypes to date using cluster analysis 
methodology.7 Among 184 patients managed in primary care, 
three clusters were found: one group with benign asthma, one 
group with obese non-eosinophilic asthma and one group 
with early-onset atopic asthma (Figure 1). Cluster analysis 
of two further mostly refractory asthma populations man-
aged in secondary care (N=255 total) added an early symp-
tom predominant cluster and an inflammation predominant 
cluster. Other phenotyping studies using comparable clinical 
variables found similar phenotypes.9,13,30–32
In this study, we examined if it is possible to identify 
asthma patients with one of three phenotypes identified in 
primary care by Haldar et al from electronic health records 
and report their characteristics and medication use. To accu-
rately classify patients into a phenotype, strict criteria were 
applied. The exact criteria are described in the “Methods” 
section. Blood eosinophil tests were used as they are well 
recorded in Clinical Practice Research Datalink (CPRD), 
unlike sputum eosinophils.33
We used the CPRD GOLD database to identify asthma 
patients. To define asthma exacerbations, we also linked to 
the Hospital Episode Statistics (HES) and Office for National 
Statistics (ONS) data.
Aim and objectives
To evaluate the extent to which three previously suggested 
asthma phenotypes (benign asthma, atopic asthma, and 
obese non-eosinophilic asthma) could be identified using 
data included in routinely collected electronic health records 
and to assess the exacerbation frequency, clinical profile and 
medication use by phenotype.
Methods
Data sources
We used the July 2017 dataset of the CPRD, a large UK 
primary care database containing anonymized data of people 
registered with primary care practices from across the UK. 
Figure 1 Asthma phenotypes, based on cluster analysis.
Notes: reprinted with permission of the American Thoracic society. copyright© 2018 American Thoracic society. haldar P, Pavord iD, shaw De, Berry MA, Thomas M, 
Brightling ce, Wardlaw AJ, green rh. cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–24.7 The American Journal of respiratory 
and Critical Care Medicine is an official journal of the American Thoracic Society.
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Predefined asthma phenotypes in CPRD
CPRD is representative of the UK population with regard 
to age and sex.34,35 Diagnostic accuracy is high in CPRD, 
including for asthma and COPD,36–39 and CPRD can be used 
to identify individuals at risk of recurrent asthma attacks.40,41 
Only patients with linkage to Hospital Episodes Statistics 
(HES) and ONS were considered for inclusion. Linked data 
are available for patients registered at consenting English 
practices. This study used only data on patients who were 
linked to Hospital Episodes Statistics (HES) for all hospital 
inpatient admissions and emergency visits and ONS for 
deaths and socioeconomic status through the index of mul-
tiple deprivation (IMD).
study population and follow-up
Adult patients in CPRD (18 years of age or older) with 
linkage to HES and ONS and a validated asthma Read code 
between April 2007 and July 2017 in addition to a valid blood 
eosinophil count, body mass index (BMI) and determinable 
smoking status were eligible for inclusion.37 Patients entered 
the cohort at the latest date of: 1 year of follow-up from the 
practice up-to-standard (UTS) date (contributing research 
quality data to CPRD); reaching 18 years of age; available 
linkage and from April 2007 at earliest.
Once all these criteria were fulfilled, participants were 
assessed during one continuous year to assign them to one 
of the phenotypes. During this year, their reliever medica-
tion (short-acting beta agonist [SABA]) and maintenance 
treatment prescriptions (refer the “Definitions of covariates” 
section) were measured. The time point after 1 year when 
patients were assigned to a phenotype and after which exac-
erbations were measured was designated as the index date 
(Figure 2). We used SABA prescription count as proxy for 
symptom expression,42,43 as asthma symptoms are nonspecific 
and often not recorded in CPRD. Blood eosinophil counts, 
routinely recorded in primary care, were used as proxy for 
sputum eosinophil counts.33,41,44 Patients were assigned their 
phenotype group on index date, after which severe asthma 
exacerbations were ascertained and counted. Patients 
remained in their respective phenotype group and followed 
up until the earliest date of transfer-out of CPRD practice, last 
collection date, death or end of study period (01/07/2017).
Definition of the phenotypes
Each patient was assigned to a single phenotype group 
on index date based on previously recorded information. 
Stringent inclusion criteria were used to keep the phenotype 
groups specific. All code lists for covariates and comorbidities 
are included in attachment and on Data compass. Patients 
were only allowed to be classified into a single phenotype. 
Obese non-eosinophilic asthma held priority over atopic 
asthma as the former phenotype was deemed more specific. 
Phenotype groups were defined as follows:
1. Benign asthma: low eosinophil counts on the latest blood 
test from April 2007 onward (<300 cells/µL45,46 and <4% 
of leukocytes), absence of SABA prescriptions and of 
severe exacerbations of asthma in the year before index 
date, and aged 40–60 years at study entry. The term 
Figure 2 cohort timeline.
Abbreviations: BMi, body mass index; UTs, up-to-standard.
Cohort entry: Index date:
Follow-up
start
Practice UTS
18 or older
Linkage available
Validated asthma
diagnosis
After 4/2007
Cohort entry:
Transfer out
Last data
collection
After 6/2017
Death
1 year to record
treatment
April 2007:
Study start
June 2017:
Study end
Last eosinophil test
Atopy & antihistamines
Last BMI in 5 years before index
Smoking history
Vacations in 10 years before index
Follow-up, registration of exacerbations
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“benign asthma” may not be accurate since even mild 
and/or under treated patients may have lung inflammation. 
However, this term was kept as it was used in the cluster 
analysis7 and to avoid confusion in this paper.
2. Atopic asthma: occasional SABA prescriptions (2–4 in 
year before index date, excluding 23% of patients without 
SABA prescriptions and 26% with 5+ prescriptions) and 
≥1 atopy or ≥2 antihistamine codes ever recorded.
3. Obese non-eosinophilic asthma: low eosinophil counts 
on the last blood count (ie, blood eosinophil levels less 
than 300 cells/µL and less than 4% of blood leukocytes), 
female, frequent SABA prescriptions (≥3 prescriptions 
in year before index date, which corresponds to 42% 
of patients) and at least one record for BMI >30 in last 
5 years before index date.
4. Asthma NOS (not otherwise specified): patients who 
did not fit in previous phenotypes were split into three 
subgroups: 1) patients without any asthma medication 
prescriptions, 2) patients only on SABA and 3) patients 
with at least one maintenance treatment prescription 
during the 1 year before index date. We described these 
groups to determine whether they fit other phenotypes 
described in the literature.
Definition of severe asthma 
exacerbations
An exacerbation was defined as any of the following: pre-
scription of ≤300 mg oral corticosteroids (OCSs) outside 
an annual asthma review47 or an accidents & emergencies 
(A&E) visit, acute hospital visit of <1 day duration, overnight 
hospitalization or death due to asthma. This corticosteroid 
dose cutoff was chosen to eliminate chronic OCS use for 
other conditions than asthma. Exacerbations within 14 days 
of a previous exacerbation were excluded.
Definition of covariates
Age was defined in 10-year age bands, socioeconomic status 
was assigned at patient level using the ONS IMD. Smok-
ing status was categorized as current smoker, ex-smoker or 
never-smoker. Comorbid conditions were determined by Read 
codes: COPD, atopic dermatitis, GORD (gastro-oesophageal 
reflux disease), atopy (eczema or rhinitis), anxiety and depres-
sion. Influenza and pneumococcal vaccinations during last 
10 years were included as covariates. The final model was 
stratified by disease severity based on the stepwise approach 
in the 2016 British Thoracic Society/Scottish Intercollegiate 
Guidelines Network (BTS/SIGN) Asthma Management 
Guidelines, which includes inhaled corticosteroids (ICS) 
thresholds.47 Step 1 was defined by the absence of maintenance 
asthma treatment. Step 2 by regular prescription of low-dose 
ICS. Step 3 added long-acting beta agonist [(LABA]. Step 
4 by medium-dose ICS with or without additional therapies 
(LABA, theophyllines, leukotriene receptor antagonists or 
long-acting antimuscarinics). Step 5 was defined by high-dose 
ICS and step 6 by continuous/frequent use of OCSs.
Data analyses
Baseline characteristics were tabulated for each phenotype. 
Asthma exacerbation incidence rates and rate ratios were 
calculated using negative binomial regression with a ran-
dom effects model and lexis expansion for age. We used 
negative binomial regression over Poisson regression with 
overdispersion as it provides a better fit to the distribution of 
the data.48,49 The minimally adjusted model included age and 
sex only. The fully adjusted model additionally controlled for 
smoking status, BMI, socioeconomic status, GORD, pneu-
mococcal and influenza vaccinations, anxiety, depression and 
COPD. In addition, we stratified incidence rate ratios (IRRs) 
by severity, defined by prescribed treatment. Stata 15.0 was 
used for data analysis. Results were displayed using forest 
plots and a Kaplan–Meier survival plot to display time to 
first exacerbation.
Results
Background characteristics
Of 323,862 asthma patients with complete linkages and 
eligible for inclusion, 193,999 (59.9%) had at least 1 year 
of follow-up and an eosinophil count, BMI value and smok-
ing variables and formed the analysis population ( Figure 3). 
Study participants were followed up for a median of 
4.24 years (interquartile range [IQR]: 1.99–6.34); the median 
age at study entry was 51 years (IQR 37–66). About 65.3% 
were female and 63.5% were smokers or ex-smokers.
In this primary care asthma population, 7,495 (3.9%) were 
classified into the benign asthma group, 55,455 (28.6%) as 
atopic asthma and 9,372 (4.8%) as obese non-eosinophilic 
asthma (Table 1). Of the remaining patients classified as 
asthma NOS, 20,204 (10.4%) did not receive any asthma 
medication, 11,926 (6.1%) had only SABA prescription 
codes and 89,547 patients (46.2%) had maintenance treat-
ment in the year before index date.
The patient characteristics and total follow-up dura-
tion varied between phenotypes. The asthma NOS group 
with maintenance treatment had the highest mean age on 
study entry (55 years, SD 18 years). Average BTS step was 
highest in the same group (mean 3.38), followed by obese 
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 non-eosinophilic and atopic asthma (Figure 4). GORD and 
anxiety were most common in the obese non-eosinophilic 
group (25.3% and 38.2%, respectively), followed by atopic 
asthma and asthma NOS with maintenance treatment. 
Comorbid COPD was most common in the asthma NOS 
group with maintenance asthma treatment (22.9%). The 
last available eosinophil count was elevated in 50.2% of all 
patients and 65.8% were overweight or obese.
severe exacerbation rates
The study participants were followed for a total of 
819,619 years and 258,388 exacerbations were recorded 
(Table 2). Exacerbation rates (per 1,000 person-years) were 
highest in the obese non-eosinophilic group and lowest in 
the benign asthma group. Minimally adjusted exacerbation 
rates per phenotype were as follows: 116.2 for benign asthma, 
286.9 for atopic asthma, 454.9 for obese non-eosinophilic 
asthma, 148.1 for asthma NOS without medication, 208.6 for 
asthma with only SABA prescriptions and 389.4 for asthma 
NOS with maintenance medication.
Figure 3 Flowchart of study eligibility and participation.
Abbreviations: BMI, body mass index; CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; A&E, accidents and emergencies; ONS, Office for 
National Statistics; NOS, not otherwise specified.
765,959 patients with an asthma
diagnosis after 2007 in CPDR GOLD
323,826 adult patients with linkage to HES,
HES A&E and ONS
295,013 patients with at least 1 year of
continous follow-up
201,677 with a valid eosinophil count
193,999 with recorded BMI and smoking
variables
442,097 patients excluded without
linkage or younger than 18
28,849 patients excluded without one
year of continous follow-up
93,336 patients excluded without a
valid eosinophil count
7,678 patients excluded without
variables to determine BMI or smoking
Asthma NOS
with
maintenance
treatment:
N=89,547
Asthma NOS
with only
reliever
treatment:
N=11,926
Asthma NOS
without
medication:
N=20,204
Obese non-
eosinophilic
asthma:
N=9,372
Atopic
asthma:
N=55,455
Benign
asthma:
N=7,495
Fully adjusted exacerbation rates controlling for lifestyle 
factors and comorbidities show a similar relation between 
asthma phenotypes with event rates of 143.2 for benign 
asthma, 322.1 for atopic asthma, 439.3 for obese non-eosin-
ophilic asthma, 174.6 for asthma NOS without medication, 
240.0 for asthma NOS with only SABA prescriptions and 
414.0 for asthma NOS with maintenance treatment.
rate ratios
Benign asthma had the lowest rate of exacerbations and was 
used as reference group for the calculation of IRRs (Figure 5). 
IRRs (fully adjusted models) for asthma exacerbation were 
2.28 (95% CI 2.16–2.41) for those with atopy, 3.11 (95% CI 
2.91–3.32) for obese non-eosinophilic asthma, 1.23 (95% CI 
1.16–1.31) for asthma NOS without medication, 1.69 (95% 
CI 1.58–1.80) for asthma NOS with SABA and 2.92 (95% 
CI 2.77–3.08) for asthma NOS with maintenance treatment. 
When stratified by BTS treatment step, the IRRs of all phe-
notypes compared to benign asthma decreased across all 
steps, but difference in incidence rates between the groups 
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Predefined asthma phenotypes in CPRD
and benign asthma was still notable. Time to first exacerbation 
analysis showed a pattern comparable with rates derived by 
negative binomial regression (Figure 6). Shortest median time 
to exacerbation was observed in the obese non-eosinophilic 
asthma group, and longest in the benign asthma group. No 
clinically important interaction between phenotype and age 
or phenotype and gender was observed. Sensitivity analyses 
including patients with missing BMI or smoking status found 
similar results to the main analysis.
Discussion
summary
In this study on asthma phenotypes in a large general asthma 
population, we were able to identify patients who fitted three 
previously suggested phenotypes: benign, early-onset atopic 
and obese non-eosinophilic asthma. Large electronic health 
record (EHR) databases may be used to identify cohorts 
for future study and sub analysis may be considered. Due 
to strict criteria used to define the three main phenotypes, 
most patients with asthma (62.7%) were not included in any 
of the three predefined primary care phenotypes and were 
categorized as asthma NOS. Patients in the asthma NOS 
groups partly reflected some of the established phenotypes, 
for example, inflammation predominant or early symptom 
predominant phenotypes. For example, in the asthma NOS 
with maintenance treatment group, 57.0% of patients had 
high eosinophil counts; possibly indicating some patients 
with an inflammation predominant phenotype were included 
in this group. However, these patients also had more SABA 
prescriptions (and presumably more symptoms) than the total 
cohort. This group may include undiagnosed COPD patients 
based on their higher average age and treatment step. There 
was a higher exacerbation burden in those with obese non-
eosinophilic atopic asthma, and a lower exacerbation rate 
in those with benign asthma compared to the asthma NOS 
group (with and without medication) in the crude model. 
These rate differences persisted after adjustment for lifestyle 
factors and comorbidities. When stratifying the patients 
by treatment step, differences in incidence rates between 
phenotypes remained but were decreased. Phenotyping a 
greater proportion of asthma patients based on their primary 
care health records could be possible by either constructing 
different phenotypes or by creating more complete records 
(for example, more full blood counts). However, this might 
not be the most efficient way to offer precision medicine 
to asthma patients. The recently proposed treatable traits 
strategy6,50 might represent a better conceptual framework 
toward precision medicine for asthma than phenotyping using 
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primary care EHR at this stage.51,52 This strategy focuses 
asthma management on single traits that are identifiable 
and treatable, such as airway inflammation (measured using 
eosinophil counts) or airflow limitation.6
There are multiple strengths to the current study. The 
CPRD GOLD is population-based and representative of the 
population of England34 which allows estimation of asthma 
phenotype prevalence, and the median length of follow-up 
is considerable (4.1 years). Further strengths include the 
detailed methods to define the dependent (exacerbation rate) 
and independent (phenotype) variable and the inclusion of 
exacerbations in primary, secondary and emergency care, in 
addition to asthma deaths. The asthma codes in the CPRD 
have been validated in a previous validation study using 
general practitioner (GP) questionnaires.37
comparison with existing literature
In the past, phenotype categorization was mostly based on 
variables such as age of onset, severity, reaction to treatment 
or comorbidities. More recently, cluster analysis of clinical 
variables including airflow measurements has been used to 
describe phenotypes. These cluster analyses have all been 
limited in terms of sample size7,9,15,30,31 or were preselected 
such as severe asthma populations.53 To the best of our 
knowledge, this is the first longitudinal study on a general 
population-wide asthma cohort. As such, it is difficult to draw 
direct comparisons between this population-based asthma 
study and previous phenotyping studies.
In the categorization by Haldar et al, the three pheno-
types we focused on here were described in a primary care 
cohort of 184 patients. In this cohort, 96 (52%) patients had 
Figure 4 BTs step by phenotype.
Abbreviations: BTS, British Thoracic Society; eos, eosinophilic; NOS, not otherwise specified; SABA, short-acting beta agonist; Tx, treatment.
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Table 2 exacerbation rates by phenotype
Phenotype No. of 
events
Time at risk  
(1,000 person-years)
Crude rate/1,000  
person-years (95% CI)
Minimally adjusted Adjusted rates
Benign asthma 3,431 30.867 106.8 (101.2–112.3) 116.2 (110.1–122.3) 143.2 (135.6–150.8)
Atopic asthma 68,143 239.664 283.2 (278.6–287.7) 286.9 (282.3–291.5) 322.1 (316.6–327.5)
Obese non-eosinophilic 19,263 42.471 469.0 (451.7–486.2) 454.9 (438.0–471.7) 439.3 (422.5–456.2)
nOs no medication 10,495 70.978 143.8 (139.3–148.3) 148.1 (143.4–152.7) 174.6 (169.0–180.2)
nOs with reliever Tx 9,529 48.238 200.7 (193.2–208.1) 208.6 (200.9–216.3) 240.0 (231.1–249.0)
nOs with maintenance Tx 1,47,527 387.403 388.2 (383.5–392.9) 389.4 (384.6–394.1) 414.0 (408.6–419.3)
Notes: Minimally adjusted: adjusted for age and sex. Adjusted rates: adjusted for age, sex, smoking, BMi, iMD, anxiety, depression, cOPD, gOrD, vaccination status and 
asthma treatment step. Unless otherwise indicated, values are given as rates (95% ci).
Abbreviations: BMI, body mass index; GORD, gastro-oesophageal reflux disease; IMD, index of multiple deprivation; NOS, not otherwise specified; Tx, treatment.
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
80
.2
29
.2
44
 o
n 
02
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2019:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
15
Predefined asthma phenotypes in CPRD
Figure 5 IRRs, stratified by treatment step.
Notes: Adjustment for step 6 resulted in very wide cis due to low sample size. This made the forest plot unreadable, so this adjustment is not displayed.
Abbreviations: BTS, British Thoracic Society; IRR, incidence rate ratio; med; medication; NOS, not otherwise specified.
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benign asthma, 61 (33%) had early-onset atopic asthma and 
27 (15%) had obese non-eosinophilic asthma. In addition, 
two more phenotypes were identified from two separate 
populations (including a secondary care and a longitudinal 
study of mostly refractory patients). The early onset symptom 
predominant phenotype has high symptom expression and a 
tendency toward overtreatment, while the inflammation-pre-
dominant asthma phenotype has a lower symptom expression, 
but active eosinophilic inflammation. Another well-known 
categorization of asthma phenotypes was undertaken by 
Moore et al9 using cluster analysis in the USA Severe Asthma 
Research Program based on respiratory function and age-
of-onset. While this analysis was heavily based on the latter 
(unfortunately routinely collected electronic records often 
lack information on age-of-onset), the obese non-eosinophilic 
asthma and early-onset atopic asthma were also identified. 
The exacerbation frequency is similar to those of previous 
studies on asthma exacerbation rates in the UK.40,41 Compari-
son of exacerbation rates between countries remains difficult 
without consensus on the definition of asthma.6,54
limitations
The main limitation of this study is due to the nature of 
routinely collected data. For example, the CPRD does not 
hold information on the age of onset, which is one of the 
defining traits of the early-onset atopic asthma phenotype. 
Our inability to identify phenotype for a sizable proportion of 
the population highlights the need for developing phenotypes 
that can be more readily identified from routine care records, 
as well as the need for improving routine care records so that 
important phenotypes can be identified.
Residual confounding remains possible, despite the 
adjustment for several potential confounders. Misclassifica-
tion of asthma is possible, but Read codes for asthma have a 
high positive predictive value (PPV) (86%) in CPRD.37 The 
exacerbation cutoff of ≤300 mg OCSs might have misclassi-
fied some patients. The blood eosinophil cutoff at <300 cells/
µL for “eosinophilic asthma” is not absolute, and multiple 
different eosinophil levels are used in the literature.55–58 Blood 
eosinophil counts were used as they are a practical alterna-
tive to predict sputum eosinophilia and are available in the 
Figure 6 Time to first exacerbation analysis in years, by phenotype and 95% confidence intervals.
Abbreviation: NOS, not otherwise specified.
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CPRD GOLD.59–61 Nonetheless, the original phenotypes were 
constructed using sputum eosinophilia.7 We included only 
people with full linkage; however, exclusions were at practice 
level so unlikely to bias estimates. Asthma phenotypes might 
change over follow-up, but this would remain true even in 
a cohort study identified in real time. Similarly, we assume 
eosinophil levels do not change greatly over time. This 
assumption may not always hold as eosinophil levels are fluid 
and depend on the level of steroid treatment and  inflammation 
(such as hay fever or recent viral infections). CPRD contains 
information on only prescriptions of treatments, without 
information on adherence to those treatments. In the case 
of SABA prescriptions, not all reliever treatment that was 
prescribed is necessarily used. BTS guidelines evolve over 
the years, so the treatment step given might not correspond 
exactly to the step at the time of prescription. Nonetheless, 
the BTS 2016 guidelines were used for consistency. SABA 
prescriptions are an imperfect measure for asthma symptoms, 
as some practices may prescribe SABA as part of a patient’s 
repeat prescription, and some symptomatic patients may only 
use maintenance inhalers.
Conclusion
Primary care asthma phenotypes can be identified from large 
electronic health care databases, although a large propor-
tion could not be classified. Exacerbation frequencies are 
lowest in the benign phenotype and highest for the obese 
non-eosinophilic phenotype. Phenotyping along with the 
knowledge of asthma treatment step could help anticipate 
future treatment needs but is only possible in a minority of 
asthma patients based on current phenotypes and primary 
care records.
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